Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation

Aromatase inhibitors are used to treat oestrogen receptor positive breast cancers but the molecular basis for the response of patients is unclear. Here, the authors use samples from an aromatase inhibitor clinical trial and show that tumours from poor responders have more mutations than good respond...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pascal Gellert, Corrinne V. Segal, Qiong Gao, Elena López-Knowles, Lesley-Ann Martin, Andrew Dodson, Tiandao Li, Christopher A. Miller, Charles Lu, Elaine R. Mardis, Alexa Gillman, James Morden, Manuela Graf, Kally Sidhu, Abigail Evans, Michael Shere, Christopher Holcombe, Stuart A. McIntosh, Nigel Bundred, Anthony Skene, William Maxwell, John Robertson, Judith M. Bliss, Ian Smith, Mitch Dowsett, POETIC Trial Management Group and Trialists
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2016
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/555df6a99ecd4105b13f149fab06246c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation

Ejemplares similares